Acute Myeloid Leukemia Coverage From Every Angle

Recent News

Intravenous and Subcutaneous Cytarabine for Standard Induction Therapy in AML
Quizartinib-Based Triplet Therapy for FLT3-ITD–Mutated AML
5-Year Results for CPX-351 in Older Adults With High-Risk AML
Safety Profile of Midostaurin in Older Patients With AML
Oral Azacitidine as Maintenance Therapy for Acute Myeloid Leukemia
Race Matters Significantly in AML Outcomes, Study Data Show
ASH 2020: Phase III Trial of Gilteritinib Plus Azacitidine for FLT3-Mutated AML
ASH 2020: Gilteritinib Versus Salvage Chemotherapy for FLT3-Mutated AML
COVID-19 and Acute Leukemias: German Investigators Share Treatment Experiences
ASH 2020: Venetoclax Plus CPX-351 in AML
ASH 2020: Early Results in Targeting CD47 in AML
FDA Brief: Eprenetapopt Given Fast Track Designation for TP53-Mutant AML
Altered Bone Marrow Niche: Predicting Outcomes in AML?
Precision Medicine in AML Early Results From Beat AML Master Trial
Relapsed AML in Children and Hematopoietic Cell Transplantation
Predicting Low-Risk Febrile Neutropenia in Chemotherapy-Treated Patients With AML
Suicide Risk Factors for Patients With AML and Other Leukemias
Anti–TIM-3 Monoclonal Antibody Under Study in AML
Rare Occurrence of Secondary CML After AML: Case Study
Novel Treatment Under Study in Transplantation-Eligible Patients With AML
Early Results With Eftozanermin Alfa Plus Venetoclax in AML
How Does Minimal Residual Disease Impact Clinical Outcomes in Acute Leukemias?
Venetoclax Combination Therapy for Acute Myeloid Leukemia Approved by FDA
Potential of IDH1 Inhibitors in AML Prior to Hematopoietic Cell Transplantation
SIERRA Trial Update on Novel Conditioning Regimen for Older Patients With AML
Pediatric AML: Combination Therapy With Venetoclax and Azacitidine
SOHO 2020: GI Side Effects for Patients With AML Treated With CC-486
SOHO 2020: Survival Update From BRIGHT Trial of Glasdegib-Based Therapy for AML
Long-Term Psychosocial and Neurocognitive Impact of Childhood AML
SOHO 2020: Elevated LDH Levels and Overall Survival in AML
Clinical Implications of Condensing HDAC Regimen in Treatment of AML
NPM1‐Mutant AML and COVID-19: Modified Protocols for Monitoring Treatment Response
Stem Cell Transplantation and AML: WT1 Expression and Outcomes
Azacitidine Tablets Approved by FDA for Patients With AML in First Remission
Selinexor in Refractory Oligoblastic AML: Phase II Trial Findings
AML and COVID-19: Treatment Lessons Learned
Glasdegib After Transplantation in Patients With AML at High Risk for Relapse
Does Treatment Delay Affect Outcomes in AML?
Personalized Immunotherapy for Resistant AML
Antimetabolite Aspacytarabine Receives Fast Track Designation for AML Treatment
New ASH Guidelines Focus on Managing AML in Older Adults
Use of Anthracyclines and Stem Cell Transplantation in AML: Outcomes by Age
Primary Antifungal Prophylaxis in Patients Treated for Acute Myeloid Leukemia
Factors Predictive of Response to Venetoclax Treatment in AML
Third-Generation BCR-ABL Inhibitor Under Study in AML

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.